Which neurotransmitter hypothesis is most strongly supported by the therapeutic response of schizophrenia patients to antipsychotic drugs?

Explanation

## The Dopamine Hypothesis of Schizophrenia **Key Point:** The dopamine hypothesis remains the cornerstone of schizophrenia neurochemistry and is the most empirically supported explanation for antipsychotic drug action. ### The Dopamine Hypothesis: Core Mechanism **High-Yield:** All effective antipsychotics block dopamine D~2~ receptors. The strength of D~2~ receptor blockade correlates with antipsychotic potency and therapeutic efficacy. ### Dopaminergic Dysfunction in Schizophrenia ```mermaid flowchart TD A[Schizophrenia pathophysiology]:::outcome --> B{Dopamine dysregulation}:::decision B -->|Mesolimbic pathway<br/>hyperactivity| C[Positive symptoms<br/>Hallucinations, delusions]:::outcome B -->|Mesocortical pathway<br/>hypoactivity| D[Negative symptoms<br/>Alogia, avolition, affective flattening]:::outcome E[Antipsychotic drugs<br/>D2 blockade]:::action --> C E --> D F[Rapid D2 blockade<br/>Hours to days]:::action --> G[Positive symptom relief]:::outcome H[Gradual mesocortical<br/>rebalancing<br/>Weeks to months]:::action --> I[Partial negative symptom improvement]:::outcome ``` ### Evidence Supporting the Dopamine Hypothesis | Evidence | Details | |----------|----------| | **D~2~ receptor occupancy** | Antipsychotic efficacy correlates with 60–80% D~2~ receptor occupancy in striatum | | **Clinical response timeline** | Positive symptoms respond within days; negative symptoms take weeks–months | | **Dopamine agonists** | Drugs that increase dopamine (e.g., amphetamines, L-DOPA) can exacerbate or precipitate psychosis | | **Imaging studies** | PET/SPECT show elevated dopamine release in mesolimbic regions in untreated schizophrenia | | **Antipsychotic classification** | Both typical (high D~2~ affinity) and atypical (lower D~2~ affinity + 5-HT~2A~ antagonism) are effective | **Clinical Pearl:** The dopamine hypothesis explains why antipsychotics work but does NOT fully explain schizophrenia's etiology—it is a pharmacological observation, not a complete disease model. Negative symptoms and cognitive deficits respond poorly to dopamine blockade alone, suggesting additional neurotransmitter involvement. **Mnemonic:** **DOPA** — Dopamine Occupancy Predicts Antipsychotic efficacy. ### Why Other Hypotheses Are Secondary - **Serotonin hypothesis:** Atypical antipsychotics block 5-HT~2A~ receptors, but this is not required for efficacy; typical antipsychotics (which lack 5-HT~2A~ antagonism) are equally effective for positive symptoms. - **GABA hypothesis:** No primary GABA dysfunction identified; GABAergic drugs are not antipsychotics. - **Glutamate excess hypothesis:** Emerging evidence supports NMDA receptor hypofunction, but glutamate-modulating drugs are not yet standard treatment; dopamine blockade remains the gold standard. [cite:Harrison 21e Ch 397]